#Japan #Endometriosis #Kanagawa #AglyMax® #Nichimo Bio

Recent Findings on AglyMax® and Endometriosis Treatment

The use of AglyMax®, developed by Nichimo BiOTex, is gaining attention for its potential benefits in alleviating symptoms of endometriosis, a chronic inflammatory condition affecting approximately 10% of women of reproductive age. Recent findings were presented during a seminar at the 26th Annual Meeting of the Japanese Society of Anti-Aging Medicine, held in Kanagawa, where Dr. Taisuke Mori, Professor of Gynecological Medicine at Kyoto Prefectural University of Medicine, shared crucial results from a double-blind trial showing significant pain reduction in patients with endometriosis.

Understanding Endometriosis

Endometriosis can lead to debilitating pain, including severe menstrual cramps and chronic pelvic pain. The standard treatment options primarily involve hormonal therapies such as GnRH agonists/antagonists and progestins, which often prevent ovulation. However, these treatments pose difficulties for women who wish to conceive, creating a pressing need for effective alternatives.

The Role of AglyMax® in Therapy

AglyMax® is a novel isoflavone supplement derived from fermented soybeans, utilizing unique koji fermentation technology patented in the United States, Japan, and Europe. Nichimo BiOTex has conducted extensive research alongside numerous esteemed academic institutions for years, accumulating a wealth of evidence supporting AglyMax®'s effectiveness in treating various health issues, including menopausal symptoms and improvements in fertility rates through LIF production.

In a pilot study reported in 2018 at the 41st Endometriosis Society Congress, the initial findings regarding AglyMax®'s role in treating endometriosis were positive, leading to the advancement of its research and subsequent new clinical trials. In 2021, a patent was registered for a formulation aimed at improving endometriosis through AglyMax®, emphasizing the focus of Nichimo BiOTex on developing innovative health solutions for women.

Seminar Highlights

During the seminar, Dr. Mori provided insights into the molecular mechanisms underpinning AglyMax® and its application in a double-blind clinical setting. The study utilized a daidzein-rich isoflavone aglycone formulation, which demonstrated the ability to suppress cell proliferation and the expression of inflammation-related factors such as IL-6, IL-8, and COX-2. Additionally, this formulation was shown to control local estrogen metabolism, as evidenced by modulation of HSD17β1 and an increase in estrogen sulfate transferase activity.

The randomized controlled trial conducted revealed that after three months of treatment with DRIAs, there was a significant improvement in endometriosis-related pain, presenting a novel non-hormonal treatment avenue that does not inhibit ovulation.

Conclusion

The findings from this research offer hope and potential solutions for women suffering from endometriosis who are seeking effective treatments without the complications of hormonal therapies. The ability of AglyMax® to provide relief from pain symptoms stands to advance conversations around alternative therapies for endometriosis, ultimately improving the quality of life for many.

For further inquiries regarding AglyMax® and its benefits, please reach out to Nichimo BiOTex's Sales Department at 03-6478-5060.